

# Esophageal Cancer Market Report 2034: Epidemiology, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight

*Companies working in the esophageal cancer market are Roche, Bristol-Myers Squibb, Merck & Co, AstraZeneca, Pfizer, Sanofi, Amgen, and others.*

LAS VEGAS, NV, UNITED STATES, January 6, 2025 /EINPresswire.com/ -- DelveInsight's "Esophageal Cancer Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Esophageal Cancer, historical and forecasted epidemiology as well as the Esophageal Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Esophageal Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Esophageal Cancer Market Forecast](#)

Some of the key facts of the Esophageal Cancer Market Report:

The Esophageal Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

In 2023, the 7MM reported approximately 77,000 newly diagnosed cases of esophageal cancer, with Japan recording the highest number, followed by the United States and the UK. Nearly 80% of cases in the US were among males.

The treatment pipeline for esophageal cancer includes drugs targeting various therapeutic lines, as well as adjuvant and neoadjuvant settings. Promising candidates expected to impact the market significantly during the forecast period include zanidatamab, bemarituzumab, and others.

The esophageal cancer market in the 7MM was valued at approximately USD 1,000 million in 2023, with the United States accounting for the largest share (40%).

In 2023, Japan recorded the highest number of total diagnosed esophageal cancer cases (~26,000) among the seven major markets, followed by the United States.

By age group, individuals aged 65 and older represented the largest portion of esophageal cancer cases in 2023, while the under-45 age group had the fewest cases in the United States. Males accounted for 80% of esophageal cancer cases in the US in 2023, with females representing 20%.

In terms of histology-specific cases, non-squamous esophageal cancer accounted for approximately 12,500 cases, while squamous esophageal cancer was found in about 7,300 cases

in the US during 2023.

In March 2024, the US FDA approved TEVIMBRA (tislelizumab) as a monotherapy for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who had prior systemic chemotherapy that did not involve a PD-(L)1 inhibitor.

Key Esophageal Cancer Companies: Roche, Bristol-Myers Squibb, Merck & Co, AstraZeneca, Pfizer, Sanofi, Amgen, and others

Key Esophageal Cancer Therapies: CYRAMZA (ramucirumab), VITRAKVI (larotrectinib), Zanidatamab, Bemarituzumab, and others

The Esophageal Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Esophageal Cancer pipeline products will significantly revolutionize the Esophageal Cancer market dynamics.

### Esophageal Cancer Overview

Esophageal cancer occurs when cancerous cells form in the esophagus, the tube-like structure connecting the throat to the stomach that facilitates food transport. The disease typically starts in the inner lining of the esophagus and can spread to its other layers and to distant organs (metastasis).

Symptoms often do not manifest until the tumor becomes large enough to interfere with eating, swallowing, or digestion. The most common symptom is difficulty swallowing, often accompanied by the sensation of food being stuck in the throat, and in some cases, choking. As the tumor grows and narrows the esophagus, swallowing becomes increasingly painful and difficult.

Esophageal cancer is usually identified through symptoms or signs, followed by exams, tests, and a biopsy to confirm the diagnosis. If cancer is detected, additional tests determine its stage. While late-stage esophageal cancer has a poor prognosis, early detection allows for potentially curative treatments. Because the disease progresses gradually before noticeable symptoms appear, pre-symptomatic screening can improve outcomes. Advances in early detection, including blood tests, advanced endoscopic imaging, and artificial intelligence, offer hope for better diagnosis and treatment.

Get a Free sample for the Esophageal Cancer Market Forecast, Size & Share Analysis Report:

<https://www.delveinsight.com/report-store/Esophageal> Cancer-market

### Esophageal Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

### Esophageal Cancer Epidemiology Segmentation:

The Esophageal Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Diagnosed Prevalence of Esophageal Cancer in Adults

Diagnosed Prevalence of Esophageal Cancer in Pediatrics

Diagnosed Prevalence of Esophageal Cancer by Types

Diagnosed Prevalence of Esophageal Cancer by Location

Diagnosed Prevalence of Esophageal Cancer by Severity

Download the report to understand which factors are driving Esophageal Cancer epidemiology trends @ [Esophageal Cancer Epidemiology Forecast](#)

Esophageal Cancer Marketed Drugs

CYRAMZA (ramucirumab): Eli Lilly and Company

VITRAKVI (larotrectinib): Bayer

Esophageal Cancer Emerging Drugs

Zanidatamab: Zymeworks/Jazz Pharmaceuticals

Bemarituzumab: Amgen

Esophageal Cancer Therapies

CYRAMZA (ramucirumab), VITRAKVI (larotrectinib), Zanidatamab, Bemarituzumab, and others

Esophageal Cancer Key Companies

Roche, Bristol-Myers Squibb, Merck & Co, AstraZeneca, Pfizer, Sanofi, Amgen, and others

Esophageal Cancer Treatment Market

Treatment for Esophageal Cancer focuses on effective diabetes management and alleviating symptoms. The first step in managing the condition is achieving glycemic control, which has been shown to reduce the risk of falls and foot ulcers. The three primary components of treatment are glycemic control, proper foot care, and pain management. Commonly prescribed medications for managing neuropathic pain include Gabapentin, Pregabalin, Tricyclic Antidepressants (TCAs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), and opioids. Alternative options include antiseizure medications like carbamazepine or lamotrigine. Patients with Esophageal Cancer should work closely with their healthcare team to develop a personalized treatment plan. Since the effectiveness of therapy can vary from person to person, regular follow-up appointments are essential to monitor progress and adjust the treatment plan as needed. Ongoing diabetes management is also a key element of treating Esophageal Cancer. Notable companies, including Helixmith, Vertex Pharmaceuticals, and AstraZeneca, are conducting clinical trials with their leading candidates to explore new treatments for Esophageal Cancer.

Scope of the Esophageal Cancer Market Report

Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Esophageal Cancer Companies: Roche, Bristol-Myers Squibb, Merck & Co, AstraZeneca, Pfizer, Sanofi, Amgen, and others

Key Esophageal Cancer Therapies: CYRAMZA (ramucirumab), VITRAKVI (larotrectinib), Zanidatamab, Bemarituzumab, and others

Esophageal Cancer Therapeutic Assessment: Esophageal Cancer current marketed and Esophageal Cancer emerging therapies

Esophageal Cancer Market Dynamics: Esophageal Cancer market drivers and Esophageal Cancer market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies  
Esophageal Cancer Unmet Needs, KOL's views, Analyst's views, Esophageal Cancer Market Access and Reimbursement

To know more about Esophageal Cancer companies working in the treatment market, visit @ [Esophageal Cancer Clinical Trials and Therapeutic Assessment](#)

## Table of Contents

1. Esophageal Cancer Market Report Introduction
2. Executive Summary for Esophageal Cancer
3. SWOT analysis of Esophageal Cancer
4. Esophageal Cancer Patient Share (%) Overview at a Glance
5. Esophageal Cancer Market Overview at a Glance
6. Esophageal Cancer Disease Background and Overview
7. Esophageal Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Esophageal Cancer
9. Esophageal Cancer Current Treatment and Medical Practices
10. Esophageal Cancer Unmet Needs
11. Esophageal Cancer Emerging Therapies
12. Esophageal Cancer Market Outlook
13. Country-Wise Esophageal Cancer Market Analysis (2020–2034)
14. Esophageal Cancer Market Access and Reimbursement of Therapies
15. Esophageal Cancer Market Drivers
16. Esophageal Cancer Market Barriers
17. Esophageal Cancer Appendix
18. Esophageal Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

## Related Reports:

### Esophageal Cancer Pipeline

"Esophageal Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Esophageal Cancer market. A detailed picture of the Esophageal Cancer pipeline landscape is provided, which includes the disease overview and Esophageal Cancer treatment guidelines.

### Esophageal Cancer Epidemiology

DelveInsight's 'Esophageal Cancer Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Esophageal Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

## Latest Reports by DelveInsight

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Kritika Rehani

DelveInsight Business Research LLP

+1 469-945-7679

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/774521778>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.